S&P Futures
3,892.75 -30.00 (-0.76%) Dow Futures
31,183.00 -257.00 (-0.82%) Nasdaq Futures
11,867.25 -68.25 (-0.57%) Russell 2000 Futures
1,763.20 -9.60 (-0.54%) Crude Oil
106.44 -3.15 (-2.87%) Gold
1,839.40 +23.50 (+1.29%)
DiaSorin S.p.A. (DIA.MI)
Chart Events
Performance Outlook
| Previous Close | 115.50 |
| Open | 114.25 |
| Bid | 117.15 x 0 |
| Ask | 117.25 x 0 |
| Day's Range | 112.50 - 117.35 |
| 52 Week Range | 106.20 - 208.80 |
| Volume | |
| Avg. Volume | 164,182 |
| Market Cap | 6.411B |
| Beta (5Y Monthly) | 0.11 |
| PE Ratio (TTM) | 20.37 |
| EPS (TTM) | 5.75 |
| Earnings Date | Mar 09, 2022 - Mar 14, 2022 |
| Forward Dividend & Yield | 1.00 (0.84%) |
| Ex-Dividend Date | May 24, 2021 |
| 1y Target Est | 147.50 |
- PR Newswire
BrainStorm Announces Presentation of NurOwn® Exosome Preclinical Data at ISCT 2022 San Francisco Meeting
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced the presentation today of a poster titled, "MSC-NTF derived small extracellular vesicles display superior macrophage immunomodulation compared with vesicles derived from naĂŻve MSCs," at the International Society of Cell & Gene Therapy ISCT 2022 Meeting, being held from May 4-7, 2022 in San Francisco, CA. The poster will be presented by Dr. Kim Thacker, Senior Vice
- PR Newswire
BrainStorm Announces Upcoming Scientific Conference Presentations
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, today announces presentations at upcoming scientific conferences in May 2022. New data on the company's proprietary MSC-NTF exosome technology will be presented at ISCT 2022 (May 4 to 7 in San Francisco, CA) and at the ISEV 2022 Annual Meeting (May 25 to 29 in Lyon, France). An analysis of CSF biomarkers from the NurOwn® Phase 3 trial will be presented at the ALS Drug Devel
- PR Newswire
BrainStorm to Announce First Quarter 2022 Financial Results and Provide a Corporate Update
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders on financial results for the first quarter ended March 31, 2022, and provide a corporate update, at 8:00 a.m. Eastern Time on May 16, 2022.
